Anders Karlson

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Antivir Ther 14:75-83. 2009
  2. ncbi Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 52:240-5. 2009
  3. ncbi The effect of raltegravir on the glucuronidation of lamotrigine
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
    J Clin Pharmacol 49:1220-7. 2009
  4. ncbi Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    AIDS 24:1223-6. 2010
  5. ncbi Drug-drug interactions between raltegravir and pravastatin in healthy volunteers
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 55:82-6. 2010
  6. ncbi Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ther Drug Monit 33:32-9. 2011

Collaborators

Detail Information

Publications6

  1. ncbi Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Antivir Ther 14:75-83. 2009
    ..We aimed to determine whether patients with high EFV plasma concentrations have an increased likelihood of toxicity-driven EFV discontinuations...
  2. ncbi Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 52:240-5. 2009
    ..To establish whether efavirenz dose reduction in patients with high plasma concentrations prevents toxicity-induced efavirenz discontinuations...
  3. ncbi The effect of raltegravir on the glucuronidation of lamotrigine
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
    J Clin Pharmacol 49:1220-7. 2009
    ..The mean ratio of the AUC(0-->48) of lamotrigine-2N-glucuronide to lamotrigine was similar when lamotrigine was taken alone (0.35) or when taken with raltegravir (0.36). Raltegravir does not influence the glucuronidation of lamotrigine...
  4. ncbi Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    AIDS 24:1223-6. 2010
    ..Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir...
  5. ncbi Drug-drug interactions between raltegravir and pravastatin in healthy volunteers
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 55:82-6. 2010
    ..To evaluate the potential drug-drug interaction between raltegravir and pravastatin...
  6. ncbi Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands
    Matthijs van Luin
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ther Drug Monit 33:32-9. 2011
    ..Therapeutic drug monitoring (TDM) is recommended in several international HIV treatment guidelines. The adherence of clinicians to these recommendations is unknown. The authors evaluated the adherence to the Dutch TDM guideline of 2005...